Agios plunged 48% after its Phase III Pyrukynd trial delivered mixed results, missing key pain-crisis and fatigue endpoints. Despite strong hemoglobin gains, AGIO still seeks FDA approval.

US stocks rose on Wednesday, setting up a fourth day win as investors welcomed rising odds of a December rate cut and showed a fresh appetite for Big Tech and risk assets heading into the holiday break.

Priority Tech faces turmoil as major holder Steamboat blasts the CEO’s go-private bid as too low. With improving results and the CEO controlling 50%+, a high-stakes valuation fight is now underway.